Further study is required to better understand the prognostic value of the “tonic contraction” phenomenon in DMD patients, and whether the longer-term consequences of the pharmacological mitigation of this phenomenon via PDE5 inhibition or other means are favorable with respect to progression of cardiac disease. The gene discussed is PDE5A; the disease is heart disorder.